Robust institutional demand paired with rising default rates and liquidity stress paints a tricky landscape for investors to navigate private credit. While the yields private credit offers may entice, investors need to prepare for the nuances tied to current market conditions. The Simplify Private Credit Strategy ETF (PCR) eases the path to exposure.

Key Takeaways:

• Despite strong corporate earnings from major managers like Ares Capital (ARCC) and Blue Owl Capital, overall U.S. private credit default rates reached 6% through June 2026, driven by elevated distress across the industrial and healthcare sectors.
• PCR addresses this market bifurcation by tracking the VettaFi Private Credit Index, offering daily exchange-traded liquidity through public BDCs and CEFs while bypassing the redemption gates typical of semi-liquid structures.
• Featuring an 11.8% distribution rate as of mid-2026, PCR utilizes active credit underwriting and a proprietary long/short credit hedge derivative strategy via total return swaps to shield investor capital from rising default trends across lower-quality debt.

See More: From Institutional to Public Portfolios: Access Private Credit With PCR

PCR’s Exposure to Market Leaders

Certain institutional powerhouses continue to post strong performance, as Ares Capital’s (ARCC) solid core earnings of $0.47 per share demonstrate. Likewise, Blue Owl Capital expanded its assets under management by 12% year-over-year.

Despite this growth, broader market indicators expose the underlying stress. Fitch Ratings reported that U.S. private credit default rates climbed to 6% through June, driven by heavy stress in the industrial and healthcare sectors. This bifurcation between strong asset generation and heightened credit risk makes a compelling case for PCR. The fund tracks the VettaFi Private Credit Index, providing targeted exposure to public business development companies (BDCs) and closed-end funds (CEFs).

Crucially, PCR’s structure addresses the exact structural pressures currently facing private markets. By investing exclusively in publicly traded BDCs and CEFs, PCR offers daily exchange-traded liquidity, avoiding the redemption gates and secondary-market discounts seen in semi-liquid vehicles. Furthermore, PCR incorporates a proprietary long/short credit hedge derivative strategy using total return swaps. This mechanism allows the fund to capture high-yielding private credit income from premier managers while buffering capital against rising default trends across lower-quality debt.

Easing the Path to Private Credit Exposure

Because private credit exposure is wrapped in the convenience of an ETF, PCR’s structure addresses the structural pressures currently facing private markets. By investing exclusively in publicly traded BDCs and CEFs, PCR offers daily exchange-traded liquidity. That strategy lets PCR avoid the redemption gates and secondary-market discounts seen in semi-liquid vehicles.

Additionally, PCR incorporates a proprietary long/short credit hedge derivative strategy using total return swaps. This mechanism allows the fund to capture high-yielding private credit income from premier managers while buffering capital against rising default trends across lower-quality debt. That said, the fund has a distribution rate of 11.8% (as of June 30, 2026).

Furthermore, PCR’s active management empowers portfolio managers to apply rigorous, real-time credit underwriting and manager selection. An active mandate also allows the fund to dynamically tilt its asset allocation toward top-tier institutional private credit managers when macro conditions require greater quality to mitigate risk.

While private credit offers enticing yields, tempted investors need to know the unique challenges associated with this market. PCR is a compelling option for exposure, and an imperative one, given current credit conditions.

For more news, information, and strategy, visit the Institutional Income Strategies Content Hub.

vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.